Vitality Watch

Dossier pubmed preclinical 09-jul-2026
Animal model, organoid, or cell-culture result — not yet human

Cyclophilin D (CypD) promotes mitochondrial impairment, synaptic defects, cognitive loss, and tau pathology during aging.

Key claim: Genetic ablation of cyclophilin D in 24-month-old mice improves cognition and mitochondrial bioenergetics, closes mPTP, preserves synaptic proteins, and prevents caspase-3-cleaved tau accumulation versus age-matched wild-type mice.

Abstract

Mitochondrial dysfunction is considered a hallmark of the aging brain, and this organelle can be affected by several neurodegenerative conditions, leading to slowed bioenergetics and reduced energy production. These processes will affect neuronal communication and synaptic plasticity, generating cognitive decline during aging. Interestingly, we previously observed that mitochondrial dysfunction can be influenced by pathological forms of tau, which are posttranslational modifications of this protein implicated in neurodegeneration and aging. In this context, accumulating evidence indicates that mitochondrial impairment may be associated with activation of the mitochondrial permeability transition pore (mPTP). mPTP has been described as a critical regulator of mitochondrial function, and its pathological activation by cyclophilin D (CypD) induces neurodegeneration and reduces brain function. However, the role of CypD/mPTP on cognitive decline and its implications on tau pathology and neurodegeneration during aging has not been studied. Therefore, we evaluated the contribution of CypD/mPTP in mitochondrial dysfunction, cognitive decline, and tau pathology observed in aging animals. Aging mice lacking CypD expression (CypD-/-) (24-month-old) showed better cognitive performance, improved mitochondrial bioenergetics, increased ATP production, and mPTP closure compared with age-matched wild-type mice (24-month-old) with endogenous expression of CypD. Consequently, hippocampal tissue from aged wild-type animals showed a significant decrease in presynaptic protein levels (SV2) compared to aged CypD-/- animals. More importantly, CypD ablation prevented caspase-3 cleaved tau accumulation in the cytosolic and mitochondrial fractions of hippocampal tissue from 24-month-old mice, in contrast with wild-type aged mice that expressed endogenous CypD. These novel results indicate that CypD acts as a neurodegenerative promoter, inducing synaptic defects and cognitive decline by opening mPTP and mitochondrial dysfunction. More importantly, CypD contributes to the neurodegenerative effects of caspase-3-cleaved tau during aging, suggesting a novel neurodegenerative target induced by tau pathology.

Why this matters

Cyclophilin D and the mitochondrial permeability transition pore have been a long-standing but mostly disease-model (ischemia, early AD) target; this aged-mouse genetic ablation extends the mPTP-opening-as-driver story into normal brain aging and connects it specifically to caspase-3-cleaved tau — a proteolytic tau species distinct from the usual hyperphosphorylation narrative. It sharpens the mechanistic case for mPTP-closing or CypD-inhibiting candidates (e.g., cyclosporine analogs) as a brain-aging lever, while leaving the human translation gap unchanged.

Source

Link

Briefing card

Cyclophilin D (CypD) promotes mitochondrial impairment, synaptic defects, cognitive loss, and tau pathology during aging.
Stage: preclinical · pubmed · 09-jul-2026

If you are following CypD/mPTP inhibitor programs for neurodegeneration, this adds aged-mouse genetic evidence that the target engages cognition and tau biology in normal aging, not just disease models.

Genetic ablation of cyclophilin D in 24-month-old mice improves cognition and mitochondrial bioenergetics, closes mPTP, preserves synaptic proteins, and prevents caspase-3-cleaved tau accumulation versus age-matched wild-type mice.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.freeradbiomed.2026.07.015

build build 880 · 2bcef25 · 2026-11-18